Updates on OLUMIANT® (baricitinib) Phase 3 lupus program and FDA review for atopic dermatitis

INDIANAPOLIS , Jan. 28, 2022 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) today announced updates on the Phase 3 development program for OLUMIANT ® (baricitinib) in adults with active systemic lupus erythematosus (also referred to as SLE and lupus) and the status of